MarketCapExport financials
GoodRx Holdings (GDRX)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
GoodRx Holdings Balance Sheet 2025-2011 | GDRX
Brief overview of GoodRx Holdings's financial position
The balance sheet is assessed across five available annual reports spanning 2021 to 2025.
Assets finished at $1.4 billion versus $1.6 billion initially, losing -12.7%. The balance sheet contracted.
Asset growth of -12.7% came with a +1.5% rise in liabilities. Financial leverage became more prominent.
The share of internal funding stands at 43.9% versus 51.7% initially, providing a reasonable foundation.
Net debt equals roughly 0.37x of equity. This is a moderate load and leaves room for maneuver.
Cash accounts for 18.6% of assets versus 58.5% initially. The change indicates the degree of financial flexibility.
Retained earnings remain negative at -$1.4 billion. This may reflect past losses or substantial shareholder distributions, so earnings and buybacks provide important context.
Overall picture
Taken together, GoodRx Holdings's balance sheet indicators point to elevated risk. Asset growth does not offset weak funding sources.
Annual Balance Sheet GoodRx Holdings
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
226 M | 44 M | -18.4 M | -101 M | -279 M | -302 M | 645 M | 688 M | - | - | - | - | - | - | - |
Long Term Debt |
483 M | 487 M | 648 M | 652 M | 656 M | 660 M | 664 M | 717 M | - | - | - | - | - | - | - |
Long Term Debt Current |
4.75 M | 5.64 M | 6.18 M | 4.07 M | 5.85 M | 4.54 M | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | 699 M | 1.44 B | 1.46 B | - | - | - | - | - | - | - |
Total Current Liabilities |
246 M | 124 M | 123 M | 76.3 M | 81.1 M | 59.6 M | - | - | - | - | - | - | - | - | - |
Total Liabilities |
788 M | 663 M | 827 M | 790 M | 776 M | 759 M | 1.47 B | 1.48 B | - | - | - | - | - | - | - |
Deferred Revenue |
6.7 M | 6.04 M | 7.1 M | 7.88 M | 6.87 M | 6.85 M | 3.45 M | 258 K | - | - | - | - | - | - | - |
Retained Earnings |
-1.41 B | -1.44 B | -1.46 B | -1.45 B | -1.42 B | -1.39 B | -1.1 B | -1.16 B | - | - | - | - | - | - | - |
Total Assets |
1.4 B | 1.39 B | 1.59 B | 1.6 B | 1.61 B | 1.47 B | 387 M | 315 M | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
262 M | 448 M | 672 M | 757 M | 941 M | 969 M | 26 M | - | - | - | - | - | - | - | - |
Book Value |
616 M | 725 M | 762 M | 815 M | 832 M | 711 M | -1.09 B | -1.16 B | - | - | - | - | - | - | - |
Total Shareholders Equity |
616 M | 725 M | 762 M | 815 M | 832 M | 711 M | -1.09 B | -1.16 B | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Balance Sheet GoodRx Holdings
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
482 M | 482 M | 484 M | 485 M | 486 M | 488 M | 646 M | - | 649 M | 650 M | 651 M | 652 M | - | 654 M | 655 M | 656 M | 657 M | 658 M | 659 M | 660 M | 660 M | 660 M | 660 M | 664 M | 664 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
1.7 B | 1.4 B | 725 M | 676 M | 641 M | 658 M | 806 M | - | 827 M | 797 M | 784 M | 790 M | - | 774 M | 752 M | 776 M | 768 M | 763 M | 762 M | 759 M | 759 M | 759 M | 759 M | 737 M | 737 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
8.77 M | 8.63 M | 6.28 M | 6.08 M | 6.31 M | 6.33 M | 5.99 M | - | 8.34 M | 9.66 M | 10.8 M | 7.88 M | - | 11.5 M | 10.3 M | 6.87 M | 8.21 M | 8.9 M | 8.8 M | 6.85 M | 6.85 M | 6.85 M | 6.85 M | 3.45 M | 3.45 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-1.4 B | -1.41 B | -1.42 B | -1.42 B | -1.43 B | -1.45 B | -1.45 B | - | -1.43 B | -1.39 B | -1.45 B | -1.45 B | - | -1.4 B | -1.4 B | -1.42 B | -1.38 B | -1.36 B | -1.39 B | -1.39 B | -1.39 B | -1.39 B | -1.39 B | -1.1 B | -1.1 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
2.34 B | 2.02 B | 1.33 B | 1.32 B | 1.3 B | 1.35 B | 1.48 B | - | 1.71 B | 1.69 B | 1.61 B | 1.6 B | - | 1.59 B | 1.54 B | 1.61 B | 1.61 B | 1.59 B | 1.51 B | 1.47 B | 1.47 B | 1.47 B | 1.47 B | 387 M | 387 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
296 M | 236 M | 274 M | 281 M | 301 M | 424 M | 525 M | - | 795 M | 762 M | 761 M | 757 M | - | 731 M | 845 M | 941 M | 912 M | 895 M | 990 M | 969 M | 969 M | 969 M | 969 M | 26 M | 26 M | - | - | 34.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
648 M | 622 M | 601 M | 643 M | 654 M | 696 M | 669 M | - | 881 M | 895 M | 827 M | 815 M | - | 818 M | 787 M | 832 M | 846 M | 824 M | 749 M | 711 M | 711 M | 711 M | 711 M | -351 M | -351 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
648 M | 622 M | 601 M | 643 M | 654 M | 696 M | 669 M | 631 M | 881 M | 895 M | 827 M | 815 M | 788 M | 818 M | 787 M | 832 M | 846 M | 824 M | 749 M | 711 M | 711 M | 711 M | 711 M | -1.09 B | -1.09 B | -1.13 B | -1.15 B | -1.16 B | - | - | - | -31.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Balance Sheet is a fundamental financial report of GoodRx Holdings, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Balance sheet of other industry stocks – Health information services
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
American Well Corporation
AMWL
|
$ 13.97 | 5.91 % | $ 224 M |  USA |
 |
Evolent Health
EVH
|
$ 4.83 | -0.82 % | $ 552 M | USA |
 |
NextGen Healthcare
NXGN
|
- | - | $ 1.6 B | USA |
 |
Covetrus
CVET
|
- | - | $ 2.94 B | USA |
 |
1Life Healthcare
ONEM
|
- | - | $ 3.37 B | USA |
 |
R1 RCM
RCM
|
- | - | $ 3.81 B | USA |
 |
Change Healthcare
CHNG
|
- | - | $ 9.03 B | USA |
 |
Signify Health
SGFY
|
- | -0.02 % | $ 7.21 B | USA |
 |
Tabula Rasa HealthCare
TRHC
|
- | - | $ 255 M | USA |
 |
Cerner Corporation
CERN
|
- | - | $ 27.9 B | USA |
 |
iCAD
ICAD
|
- | - | $ 102 M | USA |
 |
Accolade
ACCD
|
- | 0.29 % | $ 206 M | USA |
 |
Allscripts Healthcare Solutions
MDRX
|
- | -10.39 % | $ 886 M | USA |
 |
NantHealth
NH
|
- | -46.64 % | $ 10.4 M | USA |
 |
Omnicell
OMCL
|
$ 36.34 | -0.41 % | $ 1.67 B | USA |
 |
OptimizeRx Corporation
OPRX
|
$ 9.37 | 4.93 % | $ 174 M | USA |
 |
Phreesia
PHR
|
$ 12.26 | 1.78 % | $ 732 M | USA |
 |
Health Catalyst
HCAT
|
$ 1.74 | -0.57 % | $ 122 M | USA |
 |
So-Young International
SY
|
$ 2.19 | -3.1 % | $ 171 M |  China |
 |
Teladoc Health
TDOC
|
$ 6.3 | 1.45 % | $ 1.11 B | USA |
 |
HealthEquity
HQY
|
$ 97.88 | 1.33 % | $ 8.43 B | USA |
 |
Veeva Systems
VEEV
|
$ 320.55 | 0.59 % | $ 52.5 B | USA |
 |
Schrödinger
SDGR
|
$ 23.9 | 2.14 % | $ 1.76 B | USA |
 |
Zhongchao
ZCMD
|
$ 1.34 | -4.96 % | $ 4.58 M | China |
 |
Castlight Health, Inc.
CSLT
|
- | -7.28 % | $ 227 M | USA |
 |
HMS Holdings Corp.
HMSY
|
- | - | $ 3.29 B | USA |
 |
Inovalon Holdings, Inc.
INOV
|
- | - | $ 6.37 B | USA |
 |
HealthStream
HSTM
|
$ 33.51 | -0.77 % | $ 1.01 B | USA |
 |
Progyny
PGNY
|
$ 28.44 | -0.49 % | $ 2.42 B | USA |
 |
10x Genomics
TXG
|
$ 75.59 | 5.78 % | $ 9.43 B | USA |
 |
Computer Programs and Systems
CPSI
|
- | 4.4 % | $ 133 M | USA |
 |
Akerna Corp.
KERN
|
- | - | $ 161 M | USA |
 |
MTBC
MTBC
|
- | -0.58 % | $ 51.7 M | USA |
 |
Premier
PINC
|
- | - | $ 2.33 B | USA |
 |
Streamline Health Solutions
STRM
|
- | - | $ 21.4 M | USA |
 |
SCWorx Corp.
WORX
|
- | - | $ 7.71 M | USA |